Comparative efficacy of topically applied flurbiprofen, diclofenac, tolmetin, and suprofen for the treatment of experimentally induced blood-aqueous barrier disruption in dogs.
OBJECTIVE
To compare the relative efficacies of 4 topical nonsteroidal anti-inflammatory drugs at preventing blood-aqueous barrier (BAB) disruption in dogs.


METHODS
1 eye of each dog was treated with 1% suspensions of diclofenac, flurbiprofen, suprofen, or tolmetin, or with control solution. After 4 applications of eyedrops at 10-minute intervals, BAB disruption was induced in the treated eye by anterior chamber paracentesis. The severity of BAB disruption was measured by anterior chamber fluorophotometry.


METHODS
40 ocular-normal dogs.


METHODS
After pretreatment with eyedrops, rapid 100-microliters nonleaking anterior chamber paracentesis was performed in 1 eye of each dog to induce BAB disruption. 1 day after paracentesis, 1 ml of 10% fluorescein sodium was injected i.v.. The amount of fluorescein entering the anterior chamber of each eye was measured 30 to 60 minutes later by use of a computerized scanning fluorophotometer. The degree of BAB disruption was determined by comparing the amount of fluorescein entering the aqueous humor of the paracentesed eye with that of the nonparacentesed eye.


RESULTS
At postparacentesis day 1, the order of statistically significant BAB-stabilizing efficacy among groups was: diclofenac > flurbiprofen > suprofen > tolmetin = control solution.


CONCLUSIONS
Topically applied 1% suspensions of diclofenac, flurbiprofen, and suprofen are effective at preventing BAB disruption after paracentesis in dogs, indicating their potential usefulness for treatment of prostaglandin-mediated ocular disease. 1% tolmetin is no more effective than control solution.
Ward
D A
DA
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville 37901-1071, USA.
D000818:Animals; D000867:Anterior Chamber / Q000378:metabolism; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D018916:Blood-Aqueous Barrier / Q000187:drug effects* / Q000502:physiology*; D004008:Diclofenac / Q000008:administration & dosage / Q000494:pharmacology*; D004285:Dogs / Q000378:metabolism / Q000502:physiology*; D005123:Eye / Q000378:metabolism; D019793:Fluorescein; D005452:Fluoresceins / Q000493:pharmacokinetics; D015590:Fluorophotometry / Q000379:methods / Q000662:veterinary; D005480:Flurbiprofen / Q000008:administration & dosage / Q000494:pharmacology*; D009799:Ocular Physiological Phenomena; D009883:Ophthalmic Solutions; D011897:Random Allocation; D013496:Suprofen / Q000008:administration & dosage / Q000494:pharmacology*; D014046:Tolmetin / Q000008:administration & dosage / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005452:Fluoresceins; D009883:Ophthalmic Solutions; D004008:Diclofenac; D005480:Flurbiprofen; D013496:Suprofen; D014046:Tolmetin; D019793:Fluorescein